New Zealand is one of the first countries in the world to announce approval of the Xeloda(capecitabine)/Taxotere(docetaxel) chemotherapy combination, a new chemotherapy regimen showing significantly superior survival in patients with metastatic breast cancer.
A global study showed that patients treated with Xeloda/Taxotere had a 23% improvement in median survival when compared to those treated with Taxotere alone.
For patients whose tumours have progressed despite first line chemotherapy treatment, the second line option of Xeloda and Taxotere may offer them an improved outcome. This means they now have a further option to discuss with their oncologist.
